The Efficacy and Adverse Effect of Polatuzumab Vedotin in Patients With Diffuse Large B Cell Lymphoma: an Observation Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
This study enrolled patients with relapsed or refractory diffuse large B cell lymphoma treated with polatuzumab vedotin-based chemoimmunotherapies. Patients were allowed to use chemotherapy regimens other than Rituximab and Bendamustine and transplantation following polatuzumab vedotin was also allowed.
详细描述
Polatuzumab vedotin has been demonstrated to be an effective treatment for patients with relapsed/refractory diffuse large B cell lymphoma in an international phase II clinical trial. The clinical trials was conducted in Europe and the United States. Although there is a phase III trial about polatuzumab vedotin in newly diagnosed patients with diffuse large B cell lymphoma, the double-blind design has limited the efficacy assessment and side effect observation, making it difficult to provide clinicians with further information.
This program hopes to evaluate the clinical course and treatment response of these patients in order to facilitate clinicians' understanding of this drug and to improve patients' quality of life and medical care, as well as to prevent the occurrence of related complications and treatment toxicity.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The informed consent form must be signed before any study specific tests or procedures are done
- •Adult male and female patients ≥20 years at the time of inclusion in the study Ability to understand and follow study-related instructions
- •Histological diagnosis of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma (B-NHL), confirmed by a biopsy of involved nodal or extranodal site. Patients with any of the following histologies can be included:
- •DLBCL not otherwise specified (NOS)
- •T-cell/histiocyte-rich large B-cell lymphoma
- •Primary cutaneous DLBCL, leg type
- •Epstein-Barr virus (EBV)-positive DLBCL, NOS
- •DLBCL associated with chronic inflammation
- •Primary mediastinal (thymic) large B-cell lymphoma Refractory disease is defined as no complete remission to first line therapy. Relapsed disease is defined as complete remission to first line therapy followed by disease relapse.
- •Subjects must have received adequate first line therapy including at a minimum: i) anti-CD20 monoclonal antibody unless Investigator determines that tumor is CD20 negative, and ii) an anthracycline containing chemotherapy Regimen
- •Women of childbearing potential must have a negative pregnancy test result within 7 days prior to the first study drug Administration
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs
- •For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm
排除标准
- •Primary or secondary central nervous system (CNS) lymphoma at the time of recruitment
- •Richter's transformation or prior chronic lymphocytic leukemia (CLL)
- •Vaccination with a live vaccine within 4 weeks prior to Treatment
- •Received polatuzumab vedotin as part of the first line therapy
- •Ongoing treatment or study procedures within any other Investigational Medicinal Product (IMP) clinical trial with the exception of follow-up. In case of a preceding clinical trial, last application of the respective IMP(s) must have been done more than five elimination half-lives before start of study medication in this trial.
- •History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies
- •History of hypersensitivity to any of the study drugs or their ingredients or to drugs with similar structure
- •Pregnancy or breastfeeding, or intending to become pregnant during the study or within 12 months after the last dose of study drug
结局指标
主要结局
Overall Survival
时间窗: through study completion, an average of 2 year
From the use of PoV to death related to any cause
次要结局
- Overall response rate(through study completion, an average of 2 year)
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability](through study completion, an average of 2 year)